1. Home
  2. BOLD vs CLPS Comparison

BOLD vs CLPS Comparison

Compare BOLD & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • CLPS
  • Stock Information
  • Founded
  • BOLD 2018
  • CLPS 2005
  • Country
  • BOLD United States
  • CLPS Hong Kong
  • Employees
  • BOLD N/A
  • CLPS N/A
  • Industry
  • BOLD
  • CLPS Computer Software: Prepackaged Software
  • Sector
  • BOLD
  • CLPS Technology
  • Exchange
  • BOLD Nasdaq
  • CLPS Nasdaq
  • Market Cap
  • BOLD 30.3M
  • CLPS 26.6M
  • IPO Year
  • BOLD 2024
  • CLPS 2018
  • Fundamental
  • Price
  • BOLD $1.44
  • CLPS $0.99
  • Analyst Decision
  • BOLD Hold
  • CLPS
  • Analyst Count
  • BOLD 1
  • CLPS 0
  • Target Price
  • BOLD N/A
  • CLPS N/A
  • AVG Volume (30 Days)
  • BOLD 61.2K
  • CLPS 5.8K
  • Earning Date
  • BOLD 05-09-2025
  • CLPS 03-05-2025
  • Dividend Yield
  • BOLD N/A
  • CLPS 12.87%
  • EPS Growth
  • BOLD N/A
  • CLPS N/A
  • EPS
  • BOLD N/A
  • CLPS N/A
  • Revenue
  • BOLD N/A
  • CLPS $153,816,045.00
  • Revenue This Year
  • BOLD N/A
  • CLPS N/A
  • Revenue Next Year
  • BOLD N/A
  • CLPS N/A
  • P/E Ratio
  • BOLD N/A
  • CLPS N/A
  • Revenue Growth
  • BOLD N/A
  • CLPS 5.81
  • 52 Week Low
  • BOLD $1.06
  • CLPS $0.68
  • 52 Week High
  • BOLD $12.26
  • CLPS $1.70
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • CLPS 46.05
  • Support Level
  • BOLD N/A
  • CLPS $0.94
  • Resistance Level
  • BOLD N/A
  • CLPS $1.00
  • Average True Range (ATR)
  • BOLD 0.00
  • CLPS 0.03
  • MACD
  • BOLD 0.00
  • CLPS 0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • CLPS 56.92

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About CLPS CLPS Incorporation

CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.

Share on Social Networks: